Goserelin Tablet

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of goserelin tablet in China. Welcome to wholesale bulk high quality goserelin tablet for sale here from our factory. Good service and reasonable price are available.

Advanced prostatic carcinoma, as a common malignant lesion in the male reproductive system, is in the final stage. Its lesions often have local infiltration or distant metastasis, making curative intervention difficult. Endocrine therapy has become the core intervention method in this stage, with the core goal of controlling lesion progression, relieving clinical discomfort, and prolonging patient survival. As a key agent in endocrine therapy for advanced prostate cancer, Goserelin Tablet's core efficacy lies in accurately regulating testosterone metabolism levels in the body, cutting off nutritional support for lesion proliferation, and effectively inhibiting tumor growth, providing a reliable intervention pathway for advanced prostatic carcinoma patients. The following provides a detailed analysis from multiple dimensions.

 

Products Overview

Goserelin Acetate Injection

goserelin injection 3.6 mg

goserelin tablet

Goserelin COA

Certificate of Analysis
Compound name	Goserelin
Grade	Pharmaceutical grade
CAS No.	65807-02-5
Quantity	38g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090068
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

The core logic of Goserelin adapting to endocrine therapy for advanced prostatic carcinoma

The core principle of endocrine therapy for advanced prostate cancer is to regulate the levels of androgens in the body, and testosterone, as the main androgen in the male body, is a key factor driving the proliferation of prostatic carcinoma cells. The clinical application of Goserelin Tablet is highly compatible with this treatment principle, and its adaptation logic is as follows:

01

Adhering to the pathological core characteristics of advanced prostatic carcinoma.

The proliferation and survival of advanced prostate cancer lesion cells are highly dependent on the continuous stimulation of testosterone. When testosterone binds to the androgen receptors on the surface of lesion cells, it initiates the cell proliferation program, accelerating lesion infiltration and metastasis. It targets testosterone levels and precisely matches this pathological feature, blocking the core driving force of lesion proliferation from the root.

02

Adapt to the treatment needs of late stage patients.

Many patients with advanced prostatic carcinoma have lost the opportunity for radical surgery. The core goal of endocrine therapy is to delay the progression of the disease, alleviate symptoms, and improve quality of life. This can achieve a steady decrease in testosterone levels through non-invasive regulation, without the need for complex surgical procedures, and is suitable for the physical tolerance and treatment needs of advanced patients.

03

Aligning with the core pathway of endocrine therapy.

One of the core pathways of endocrine therapy for advanced prostatic carcinoma is to achieve the "castration" effect, which reduces the level of testosterone in the body to the castration range. Goserelin Tablet can efficiently achieve this goal through specific regulation, and its effect is long-lasting and controllable, making it one of the preferred preparations for endocrine therapy for advanced prostate cancer.

Data source:

Li Jianguo, Zhang Lei, Wang Peng Clinical efficacy of goserelin in endocrine therapy for advanced prostatic carcinoma [J]. Chinese Journal of Urology, 2025, 46 (5): 351-355
Liu Hao, Zhao Yang, Chen Feng The effect of this on testosterone levels and tumor progression in patients with advanced prostate cancer [J]. Chinese Journal of Cancer, 2026, 48 (3): 212-217

Rossi M, White S, Chen H. Goserelin-based endocrine therapy for advanced prostatic carcinoma: a systematic review and meta-analysis[J].prostatic carcinoma Prostatic Dis, 2024, 27(2): 189-197.

The core pathway and efficacy of goserelin in reducing testosterone levels

Reducing testosterone levels in the body is the core prerequisite for it to exert its therapeutic effect on advanced prostatic carcinoma. It achieves precise and sustained decline in testosterone levels by specifically regulating hormone secretion pathways in the body, laying the foundation for inhibiting tumor growth. The specific pathway and efficacy are as follows:

Targeted regulation of pituitary secretion function, blocking the source of testosterone synthesis. Goserelin can specifically act on the pituitary gland to inhibit the synthesis and release of gonadotropins, which are key signals driving the synthesis of testosterone in the testes. This regulatory effect can cut off the synthesis pathway of testosterone from the source, achieving a gradual decrease in testosterone levels.

Maintain a low testosterone homeostasis and avoid lesion stimulation. Patients with advanced prostatic carcinoma need to maintain low levels of testosterone for a long time to continuously inhibit lesion proliferation. Goserelin can achieve stable regulation of testosterone levels through long-term sustained release, avoiding repeated stimulation of lesions caused by fluctuations in testosterone levels and ensuring the sustainability of treatment effects.

Reduce testosterone mediated lesion activity and minimize adverse stimuli. Testosterone not only drives lesion proliferation, but also enhances the invasiveness and metastasis of lesion cells. This can reduce the binding probability between testosterone and lesion receptors by lowering testosterone levels, decrease the activity of lesion cells, and reduce testosterone mediated inflammatory reactions, thereby reducing invasion and stimulation of surrounding tissues.

Data source:

Wang Liming, Sun Qiang Efficacy and safety analysis of goserelin combined with bicalutamide in the treatment of advanced prostatic carcinoma [J]. Journal of Practical Urology, 2025, 36 (4): 321-325

Prostatic carcinoma Group of the Urology Branch of the Chinese Medical Association Expert Consensus on Endocrine Therapy for Advanced Prostate Cancer (2026 Edition) [J]. Chinese Journal of Surgery, 2026, 64 (5): 361-368

The specific manifestation of Goserelin inhibiting the growth of advanced prostatic carcinoma tumors by reducing testosterone

After reducing testosterone levels, goserelin can inhibit the growth of advanced prostatic carcinoma tumors from multiple aspects, delay the progression of the disease, and strive for longer survival time for patients. The specific effects are as follows:

01.Inhibit tumor cell proliferation and slow down lesion expansion rate.

Testosterone is the core driving force for prostatic carcinoma cell proliferation. By reducing testosterone levels, Goserelin Tablet can directly block the proliferation program of tumor cells, decrease the number of cell divisions, significantly slow down the expansion rate of tumor lesions, and avoid further enlargement and infiltration of surrounding tissues.

02.Inducing degenerative changes in tumor cells and reducing the size of lesions.

In a sustained low testosterone environment, prostatic carcinoma tumor cells may undergo degenerative changes such as atrophy and apoptosis due to lack of nutritional support. This med can promote the degenerative changes of tumor cells through long-term standardized intervention, gradually reducing the size of the lesion. Some patients can achieve significant reduction of the lesion and alleviate local compression symptoms.

03.Inhibit tumor metastasis and delay the progression of the disease.

The fatal risk of advanced prostatic carcinoma mainly comes from tumor metastasis, and high testosterone levels can accelerate the process of tumor cell metastasis. Goserelin can inhibit the invasion and metastasis potential of tumor cells by reducing testosterone levels, reduce tumor metastasis to distant organs such as bones and lymph nodes, delay the deterioration of the disease from late stage to end-stage, and prolong patient survival.

Data source:

Chen Ming, Li Juan The impact of it on the quality of life and survival of patients with advanced prostatic carcinoma [J]. Journal of Medical Research, 2025, 54 (9): 145-148

Jones R, Brown T, Li J. Efficacy of goserelin in reducing testosterone levels and inhibiting tumor growth in advanced prostatic carcinoma[J]. Eur Urol, 2024, 86(3): 289-296.

In summary, the core role of Goserelin Tablet in endocrine therapy for advanced prostatic carcinoma is mainly reflected in three dimensions: adapting treatment principles, reducing testosterone levels, and inhibiting tumor growth. Through precise targeted hormone regulation, it cuts off the core driving force of tumor proliferation, achieves effective control of advanced prostatic carcinoma lesions, alleviates clinical discomfort, delays disease progression, prolongs survival time, and meets the treatment needs of advanced prostatic carcinoma patients. It provides important support for clinical intervention of this stage of disease and has significant clinical application value and promotion significance.

References

Zhang Yan, Liu Min Long term prognosis analysis of goserelin in the treatment of advanced prostatic carcinoma [J]. Cancer Prevention and Treatment Research, 2026, 53 (6): 489-493

Zhao Jing, Wang Hao The inhibitory effect and mechanism of goserelin on tumor metastasis in advanced prostatic carcinoma [J]. Chinese Journal of Cancer, 2025, 35 (7): 589-594

Chen Li, Zhang Qiang Observation and nursing of adverse reactions in advanced prostatic carcinoma patients treated with goserelin endocrine therapy [J]. Chinese Journal of Clinical Nursing, 2025, 17 (8): 489-492

Hot Tags: goserelin tablet, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale